Sport status is its own evidence field.
BPC-157
Not FDA approved; FDA identifies important compounding safety and characterization concerns.
Tesamorelin
FDA approved only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management.
MOTS-c
Not FDA approved; FDA reports no identified human exposure data for drug products containing MOTS-c.
TB-500
Not FDA approved; product identity and peptide-related impurities are material uncertainties.
Ipamorelin
No FDA-approved drug product; FDA identifies significant safety and characterization concerns for compounding.
Sermorelin
No current FDA-approved drug product identified in the August 2026 source snapshot.
CJC-1295
No FDA-approved drug product.
Thymosin Beta-4
No FDA-approved thymosin beta-4 drug product identified in the August 2026 source snapshot.
AOD-9604
No FDA-approved AOD-9604 drug product; FDA identifies limited safety information and potential concerns for compounded use.